Four doses of unpegylatedversusone dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

Four doses of unpegylatedversusone dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma

Published:2015-03-29 Issue:6 Volume:169 Page:787-794
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Bozzoli Valentina¹,Tisi Maria C.¹,Maiolo Elena¹,Alma Eleonora¹,Bellesi Silvia¹,D'Alo’ Francesco¹,Voso Maria T.¹,Leone Giuseppe¹,Hohaus Stefan¹

Affiliation:

1. Institute of Haematology; Catholic University S. Cuore; Rome Italy

Funder

Amgen

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13358/fullpdf

Reference37 articles.

1. Update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours;Aapro;European Journal of Cancer,2011

2. Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation;Barosi;Haematologica,2006

3. Novel CD20 monoclonal antibodies for lymphoma therapy;Cang;Journal of Hematology & Oncology,2012

4. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte;Coiffier;Blood,2010

5. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma;Corazzelli;Cancer Chemotherapy and Pharmacology,2009

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases receiving cytotoxic therapy: results of LEGERITY, a multicenter retrospective-and-prospective observational post-marketing study;Journal of Modern Oncology;2024-02-21

2. Effectiveness and safety of empegfilgrastim (Extimia®, BIOCAD) in patients with lymphoproliferative diseases who receive cytotoxic therapy: results of LEGERITY, the second interim analysis of multicenter retrospective-and-prospective observational post-marketing study;Journal of Modern Oncology;2022-04-30

3. Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy;Farmeconomia. Health economics and therapeutic pathways;2022-02-02

4. Chemotherapy limiting neutropenia. Is prevention required?;Oncohematology;2022-01-29

5. Risk factors for neutropenic fever in non-Hodgkin’s lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis;The Korean Journal of Internal Medicine;2021-09-01